NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals announced that its Board of Directors has approved a share repurchase program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

Alexion Pharmaceuticals (NASDAQ:ALXN) announced its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.50 by $0.18. The biopharmaceutical company had revenue of $930.90 million for the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.38 earnings per share. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

20 Wall Street analysts have issued 12-month target prices for Alexion Pharmaceuticals' shares. Their predictions range from $120.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $156.95 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.

Some companies that are related to Alexion Pharmaceuticals include Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron (REGN), Takeda Pharmaceutical (TKPYY), Astellas Pharma (ALPMY) and Shiseido (SSDOY).

News headlines about ALXN stock have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 0.05 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Alexion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.03%), Northern Trust Corp (1.28%), Franklin Resources Inc. (1.00%), BB Biotech AG (0.63%), Wells Fargo & Company MN (0.59%) and Eaton Vance Management (0.52%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Amundi Pioneer Asset Management Inc., State of Tennessee Treasury Department, Franklin Resources Inc., American Century Companies Inc., Federated Investors Inc. PA, Prudential Financial Inc. and Nuveen Asset Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, PointState Capital LP, Redmile Group LLC, Westfield Capital Management Co. LP, FIL Ltd, Braun Stacey Associates Inc., Wells Fargo & Company MN and SG Americas Securities LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $117.74.

Alexion Pharmaceuticals has a market capitalization of $26.06 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.